- Conditions
- B Cell Precursor Acute Lymphoblastic Leukemia
- Interventions
- Blinatumomab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 13
- States / cities
- Clovis, California • Duarte, California • Chicago, Illinois + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 75
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- Tarlatamab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Chicago, Illinois • Ann Arbor, Michigan + 3 more
- Conditions
- Primary Membranous Nephropathy
- Interventions
- Zanubrutinib, Tacrolimus
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 4
- States / cities
- Granada Hills, California • Palo Alto, California • Minneapolis, Minnesota + 1 more
- Conditions
- Gastroesophageal Adenocarcinoma
- Interventions
- Tislelizumab, Leucovorin, Oxaliplatin, Fluorouracil, Zanidatamab, Zolbetuximab
- Drug
- Lead sponsor
- American Association for Cancer Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Los Angeles, California • New Haven, Connecticut
- Conditions
- Advanced Malignancies
- Interventions
- Tislelizumab, Pamiparib, Temozolomide, Sitravatinib, Ociperlimab, BAT1706, Fruquintinib, BGB-15025, Zanidatamab, BGB-A445, Surzebiclimab, Lenvatinib, LBL-007
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 4
- States / cities
- Miami, Florida • New York, New York • Nashville, Tennessee + 1 more
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mantle Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Gastrointestinal Endoscopy, Rituximab, Sonrotoclax, Zanubrutinib
- Procedure · Biological · Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Mature B-Cell Malignancies
- Interventions
- Sonrotoclax, Zanubrutinib, Obinutuzumab
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 437 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Chicago, Illinois • Kansas City, Kansas + 9 more
- Conditions
- Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
- Interventions
- zanubrutinib, bendamustine, rituximab
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2031
- U.S. locations
- 12
- States / cities
- Orange, California • Chicago, Illinois • Boston, Massachusetts + 9 more
- Conditions
- Solid Tumor, Adult
- Interventions
- BGB-24714, Paclitaxel, Carboplatin, Docetaxel
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 17
- States / cities
- Gilbert, Arizona • Sarasota, Florida • St. Petersburg, Florida + 12 more
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Zanubrutinib, Obinutuzumab, Sonrotoclax
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion
- Interventions
- Surzebiclimab, Tislelizumab, Alcestobart
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 11
- States / cities
- Orange, California • Aurora, Colorado • Chicago, Illinois + 8 more
- Conditions
- Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma, Advanced Gastric Cancer, Advanced Gastroesophageal Junction Cancer, Advanced Esophageal Adenocarcinoma
- Interventions
- BGB-53038, Tislelizumab, Cetuximab
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Kansas City, Kansas • Baltimore, Maryland + 1 more
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor
- Interventions
- BGB-A3055, Tislelizumab, Chemotherapy
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 6
- States / cities
- Orlando, Florida • Iowa City, Iowa • Hackensack, New Jersey + 3 more
- Conditions
- Waldenstrom Macroglobulinemia
- Interventions
- Zanubrutinib, Bendamustine, Rituximab
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Boston, Massachusetts • Dallas, Texas
- Conditions
- Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
- Interventions
- Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 799 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 50
- States / cities
- Fresno, California • Irvine, California • Los Alamitos, California + 43 more
- Conditions
- Mantle Cell Lymphoma, B Cell Lymphoma
- Interventions
- Sonrotoclax, Zanubrutinib, Placebo
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more
- Conditions
- HR+/HER2- Breast Cancer
- Interventions
- BGB-43395, Letrozole, Abemaciclib, Palbociclib, Ribociclib
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,056 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2037
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 54 more
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
- Interventions
- Zanubrutinib
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 24
- States / cities
- Aurora, Colorado • Newark, Delaware • Fort Myers, Florida + 21 more
- Conditions
- Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer
- Interventions
- BG-68501, Fulvestrant, BGB-43395
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 6
- States / cities
- Newport Beach, California • Lake Mary, Florida • St Louis, Missouri + 3 more
- Conditions
- Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
- Interventions
- BGB-21447, Fulvestrant, BGB-43395
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Houston, Texas • Seattle, Washington
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Sonrotoclax, Zanubrutinib
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 11
- States / cities
- Weston, Florida • Marietta, Georgia • Niles, Illinois + 6 more
- Conditions
- Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
- Interventions
- Alcestobart, Tislelizumab, Bevacizumab or Bevacizumab biosimilar, Fluoropyrimidine (FP)
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 30
- States / cities
- Anchorage, Alaska • Gilbert, Arizona • Cerritos, California + 23 more
- Conditions
- Advanced Solid Tumor, Solid Tumor
- Interventions
- BGB-26808, Tislelizumab, Chemotherapy
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 337 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 9
- States / cities
- Duarte, California • Los Angeles, California • New Haven, Connecticut + 6 more
- Conditions
- Advanced Solid Tumor
- Interventions
- BGB-58067, BG-89894, Standard of Care Therapy
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 12
- States / cities
- Los Alamitos, California • Los Angeles, California • Celebration, Florida + 8 more